The epidemiological impact of blood-borne infections (HCV, HBV and HIV) in dialysis is a major concern. In the past two decades the implementation of specific recommendations for prevention has been associated with a sharp reduction of the HBV and HCV incidence in this setting. Moreover, in recent years new therapeutic agents against these viruses were introduced, resulting in a marked improvement in clinical outcomes in subjects with normal kidney function. A collaborative effort between nephrologists and infectious disease specialists should be made to extend this improvement to chronic kidney disease patients.